LOS ANGELES, CA, April 2, 2019 – ImaginAb Inc., a clinical stage immuno-oncology imaging company, today announces its Founder and Chief Scientific Officer Dr. Anna Wu, Ph.D. is scheduled to present at this year’s American Association of Cancer Research Annual Meeting (AACR). Dr. Wu will speak on Tuesday, April 2, 2019, during the session on Molecular Imaging for Cancer Immunotherapy.
American Association of Cancer Research (AACR)
March 29 – April 2, 2019, Georgia World Conference Center, Atlanta, Georgia
Founder and Chief Scientific Advisor of ImaginAb, Dr. Anna Wu, Ph.D., will speak on ‘ImmunoPET for visualization of T cell responses in immunotherapy’ during the following session:
ADT01. Molecular Imaging for Cancer Immunotherapy
Tuesday, April 2, 2019, 1:00 pm – 2:45 pm EDT, Room A411
Modulation of immune responses has now become a routine treatment option in cancer therapy. In spite of the huge success, a significant fraction of patients does not respond or develop resistance to therapy. To improve therapy outcomes, extensive efforts are focused on the development of tissue- and blood-based biomarkers that could enable patient selection. In addition to tumor and immune cell heterogeneity, activity of therapeutic agents at the disease site is critical for the success of therapy. Few studies have defined the pharmacokinetics (PK) and pharmacodynamics (PD) of immune checkpoint therapeutics at the disease site, and fewer have studied those parameters in real time and noninvasively. This session will focus on the novel tools and technologies, including Novel PET Tracers that enable real-time assessment of PK/PD of immune checkpoint therapeutics at the tumor that can be used in preclinical and clinical studies.
Anna M. Wu, Ph.D., is professor and chair of the Department of Molecular Imaging and Therapy, and co-director, Center for Theranostics within the Diabetes Metabolism Research Institute and professor in the Department of Radiation Oncology at City of Hope in Duarte, CA.
Phone: +1 310 645 1211
Optimum Strategic Communications
Mary Clark, Supriya Mathur
Phone: +44 20 3950 9144
ImaginAb Inc. is an immuno-oncology imaging company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is also developing a pipeline for other targets in oncology. ImaginAb’s products have the potential to improve patient care and lower healthcare costs.
For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com.